Are GLP-1 Agonists New, and What Does the Safety Record Show?

A Brief History: How Old Is This Drug Class?

GLP-1 receptor agonists are not a recent invention. The foundational biology dates to 1987, when Daniel Drucker's laboratory at the University of Toronto published the first detailed characterization of glucagon-like peptide-1 as an incretin that stimulated insulin secretion in a glucose-dependent manner. That discovery set two decades of translational work in motion.

The FDA approved exenatide (Byetta, AstraZeneca/Eli Lilly) on April 28, 2005, for adults with type 2 diabetes inadequately controlled on metformin or a sulfonylurea. Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the saliva of the Gila monster lizard, and it shares about 53% sequence homology with human GLP-1. Liraglutide (Victoza, Novo Nordisk) followed in January 2010, offering once-daily dosing compared with exenatide's twice-daily schedule. The FDA approval history for each agent is publicly accessible through the FDA's drug database.

By 2025, the FDA had approved seven distinct GLP-1 receptor agonists or GLP-1-containing combination products: exenatide, liraglutide, albiglutide (withdrawn from market for commercial reasons in 2018), dulaglutide, semaglutide (oral and injectable formulations), tirzepatide (a dual GIP/GLP-1 agonist), and lixisenatide (also withdrawn commercially). That progression from a twice-daily injectable in 2005 to a once-weekly subcutaneous pen or a daily oral tablet represents 20 years of pharmaceutical development, not an overnight emergence.

The public impression of GLP-1s as "new" drugs stems almost entirely from the 2021 FDA approval of semaglutide 2.4 mg (Wegovy) for chronic weight management, which attracted media coverage unlike anything the class had seen before. Semaglutide itself, however, was first approved as Ozempic for type 2 diabetes in December 2017, meaning its core safety profile had already been examined in the SUSTAIN trial program before the obesity indication arrived.

The Cardiovascular Outcome Trials: What 60,000+ Patients Showed

The FDA's 2008 guidance requiring cardiovascular outcome trials (CVOTs) for all new diabetes drugs produced the most rigorous safety and efficacy dataset the endocrine pharmacology world has seen in a generation. Every major GLP-1 agent has been tested in a large, placebo-controlled CVOT, and taken together these trials enrolled well over 60,000 high-risk patients.

The LEADER trial (N=9,340) compared liraglutide 1.8 mg with placebo in adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk over a median 3.8 years. Liraglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 13% relative to placebo (hazard ratio 0.87 to 95% CI 0.78-0.97, P<0.001 for non-inferiority; P=0.01 for superiority). LEADER results are published in the New England Journal of Medicine.

The SUSTAIN-6 trial (N=3,297) tested semaglutide 0.5 mg and 1.0 mg weekly against placebo in a similar high-risk population over 104 weeks. The semaglutide arms combined showed a 26% reduction in major adverse cardiovascular events (MACE; HR 0.74 to 95% CI 0.58-0.95, P<0.001 for non-inferiority). SUSTAIN-6 data are available at the New England Journal of Medicine.

REWIND (N=9,901) tested dulaglutide 1.5 mg weekly over a median 5.4 years, the longest CVOT follow-up in the class. Dulaglutide reduced MACE by 12% (HR 0.88 to 95% CI 0.79-0.99, P=0.026). REWIND results appear in The Lancet. That 5.4-year dataset is especially relevant to questions about long-term safety: over more than five years in nearly 10,000 patients, no unexpected serious adverse event pattern emerged.

The SELECT trial (N=17,604) extended the cardiovascular evidence into obesity without diabetes. Semaglutide 2.4 mg weekly reduced MACE by 20% in adults with obesity and pre-existing cardiovascular disease but no diabetes (HR 0.80 to 95% CI 0.72-0.90, P<0.001) over a mean 39.8 months. SELECT results are published in the New England Journal of Medicine. This is the trial that finally confirmed cardiovascular benefit in people using these drugs specifically for weight management.

Weight Loss Efficacy: The STEP Program Numbers

Efficacy data matter to safety discussions because they define the benefit side of any risk-benefit calculation. In STEP-1 (N=1,961), adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity received semaglutide 2.4 mg weekly or placebo for 68 weeks alongside lifestyle counseling. Mean weight loss was 14.9% in the semaglutide group vs. 2.4% in the placebo group (treatment difference 12.4 percentage points, 95% CI 11.5-13.4, P<0.001). Full STEP-1 data are available at the New England Journal of Medicine.

STEP-5 (N=304) extended treatment to 104 weeks and showed sustained mean weight loss of 15.2% with semaglutide vs. 2.6% with placebo. Weight regain after stopping treatment was documented in a separate 52-week extension study, with participants regaining approximately two-thirds of lost weight within one year of discontinuation. That discontinuation data point is clinically significant: it confirms these drugs manage a chronic condition rather than curing it, which in turn means patients and clinicians should weigh long-term safety carefully.

Gastrointestinal Side Effects: Frequency, Duration, and Management

Nausea is the most common adverse effect across the class. Data from clinical trials report nausea in 20-44% of patients, vomiting in 10-24%, and diarrhea in 9-30%, with rates varying by agent and dose. These symptoms are dose-dependent and largely explained by delayed gastric emptying combined with direct effects on brainstem nausea centers.

Gradual dose escalation substantially reduces discontinuation rates. In the STEP trials, the 4-step titration schedule (starting at 0.25 mg weekly and reaching 2.4 mg over 16-20 weeks) held treatment discontinuation due to GI adverse events to approximately 4.5% in the semaglutide arm vs. 0.8% in placebo. For most patients who tolerate the titration period, nausea fades significantly by week 8-12. A slower, off-label titration stretching over 6-9 months may reduce GI burden further, though randomized data on extended titration are limited.

Constipation is underappreciated. In the SURMOUNT-1 trial of tirzepatide for obesity (N=2,539), constipation occurred in 24.2% of participants in the highest dose group (15 mg) vs. 9.4% with placebo. SURMOUNT-1 results are published at the New England Journal of Medicine. Adequate hydration and dietary fiber intake should be addressed proactively.

Rare but serious GI events include gastroparesis. A 2023 pharmacoepidemiological study published in JAMA used a US commercial claims database of 4,144 patients and found GLP-1 users had a higher rate of gastroparesis-related diagnoses than users of bupropion-naltrexone. The absolute rates remained low, and the study had methodological limitations including probable channeling bias, but the signal supports clinical counseling about symptom monitoring in patients with prior gastric motility issues. That analysis is available at JAMA.

Pancreatitis: What the Trial Data Actually Demonstrate

Pancreatitis concerns with GLP-1 agonists arose from early post-market case reports and animal data suggesting that continuous GLP-1 receptor stimulation in pancreatic acinar cells might trigger inflammation. The FDA and European Medicines Agency investigated, leading to label updates in 2013. What has large-scale trial data shown since then?

A pre-specified pooled analysis of the four largest GLP-1 CVOTs (LEADER, SUSTAIN-6, REWIND, EXSCEL; combined N approximately 33,000) found that acute pancreatitis incidence did not differ significantly between GLP-1 and placebo arms. The absolute event rate was low in both groups (roughly 0.1-0.3 events per 100 patient-years), and no dose-response relationship was identified. The American Diabetes Association's Standards of Care summarizes this evidence.

Current clinical guidance: GLP-1 agonists remain contraindicated in patients with a personal history of pancreatitis, and prescribers should counsel patients to report severe, persistent abdominal pain immediately. Patients with hypertriglyceridemia above 500 mg/dL (a known pancreatitis risk factor) warrant particular attention.

Thyroid Cancer Risk: Rodent Data vs. Human Evidence

The class carries a black-box warning for thyroid C-cell tumors. This warning was added based on findings in rodent carcinogenicity studies conducted at doses and durations that exceed typical human exposure. Liraglutide and semaglutide caused dose-dependent C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rats and mice, likely because rodent thyroid C-cells express GLP-1 receptors at much higher density than human C-cells do. The FDA label for semaglutide (Ozempic) is publicly available via FDA.

Human thyroid C-cells express GLP-1 receptors at much lower levels, which is the biological basis for expecting the rodent signal may not translate directly. Epidemiological data gathered over the 15 years since liraglutide's approval are reassuring but not definitive. A 2023 observational cohort study published in JAMA Internal Medicine using the French national health database (N=2.5 million patients, follow-up 15 years) found a small but statistically significant increased relative risk of MTC in GLP-1 users (RR 1.58 to 95% CI 1.27-1.97) after a median 6.2-year latency. However, absolute numbers were very small: 76 MTC cases among GLP-1 users vs. 50 expected. That study could not fully exclude confounding by indication, as patients prescribed GLP-1 agents likely have more frequent thyroid ultrasound surveillance. The study is available at JAMA Network.

Contraindications remain firm: GLP-1 receptor agonists are contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine calcitonin screening before starting therapy is not universally recommended by guidelines, though some endocrinologists obtain a baseline calcitonin in patients with thyroid nodules.

Gallbladder Disease: An Underappreciated Signal

Gallstone disease is an adverse effect that deserves more clinical attention than it typically receives in media coverage. Rapid weight loss of any cause increases lithogenic bile composition, and GLP-1 agents accelerate that process. In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3.0 mg was associated with a cholelithiasis rate of 2.2% vs. 0.8% with placebo over 56 weeks. SCALE trial data appear in the New England Journal of Medicine.

Patients losing more than 1-1.5 kg per week should be counseled about the symptoms of gallstones, including right upper quadrant pain, particularly after fatty meals. For patients with prior cholelithiasis, a discussion with a gastroenterologist before starting therapy is reasonable.

The Thyroid-Specific Question: Should Patients With Thyroid Conditions Worry?

This question comes up frequently because the thyroid cancer warning is printed prominently on the packaging of every GLP-1 product. A clear framework helps.

For patients with hypothyroidism on levothyroxine, no direct pharmacokinetic interaction between GLP-1 agents and levothyroxine has been identified. However, delayed gastric emptying caused by GLP-1 therapy may reduce levothyroxine absorption if the tablet is taken at the same time as food consumption changes. TSH monitoring at 6-8 weeks after starting a GLP-1 agent is a practical precaution for patients on thyroid replacement therapy.

For patients with Hashimoto's thyroiditis or Graves' disease, the autoimmune mechanism of those conditions is distinct from the GLP-1 receptor signaling pathway. No credible evidence suggests GLP-1 agents worsen thyroid autoimmunity.

For patients with thyroid nodules under surveillance, the MTC contraindication applies only to nodules that are confirmed or suspected medullary thyroid carcinoma or to patients with MEN2. Patients with benign nodules, papillary microcarcinomas under active surveillance, or incidentally discovered nodules without malignant features are not categorically excluded from GLP-1 therapy. A conversation between the prescribing clinician and the endocrinologist managing the thyroid condition is the appropriate step, not automatic exclusion.

The 2023 Endocrine Society Clinical Practice Guideline on obesity pharmacotherapy states: "Prescribers should weigh the theoretical risk of medullary thyroid carcinoma, which is based on rodent data and unconfirmed in humans at population scale, against the well-documented benefits of weight reduction in patients with obesity-related comorbidities." That guideline is available through the Endocrine Society.

Drug Interactions, Contraindications, and Monitoring

GLP-1 receptor agonists slow gastric emptying. For drugs with narrow therapeutic windows that depend on predictable absorption timing, including warfarin, cyclosporine, and oral contraceptives, clinical pharmacologists recommend separating administration by at least 1 hour or switching to non-oral formulations when feasible.

Hypoglycemia is rare when GLP-1 agents are used as monotherapy because insulin secretion is glucose-dependent: the drugs amplify insulin release only when blood glucose exceeds approximately 70 mg/dL. Hypoglycemia risk increases meaningfully when these agents are combined with insulin or sulfonylureas, and dose reductions of the insulin or sulfonylurea by 20-50% are commonly required on initiation.

Renal function monitoring is recommended not because GLP-1 agents are directly nephrotoxic but because severe dehydration from vomiting can acutely worsen renal function. Patients with eGFR <15 mL/min/1.73 m² should not use exenatide; other agents have more permissive renal profiles, with liraglutide and semaglutide demonstrating renal-protective effects in their CVOTs.

Current absolute contraindications across the class: personal or family history of MTC, MEN2, prior serious hypersensitivity reaction to any GLP-1 agent, and pregnancy (FDA category X for fetal exposure in animals; women should stop treatment at least 2 months before attempting conception).

What the 2023 ADA Standards Say

The American Diabetes Association's 2023 Standards of Medical Care in Diabetes provides explicit prescribing guidance: "For patients with type 2 diabetes who have established cardiovascular disease or indicators of high cardiovascular risk, established kidney disease, or heart failure, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen, independent of baseline HbA1c or individualized HbA1c target, and in consideration of agent-specific effects on cardiovascular risk factors." The full ADA Standards document is available through Diabetes Care.

That recommendation reflects a shift from using these drugs only when glucose targets are unmet to using them proactively for organ protection. Twenty years of safety data supported that change.

Post-Market Surveillance and Ongoing Studies

The FDA's MedWatch and FAERS (FDA Adverse Event Reporting System) systems have tracked GLP-1 adverse events continuously since 2005. FAERS data are publicly searchable and show that the signal profile identified in clinical trials, primarily GI symptoms, gallbladder disease, and rare pancreatitis, has remained stable over the post-approval period without major new safety signals being identified for the core approved agents. FAERS data are searchable through the FDA.

Two large real-world studies deserve mention. The CVD-REAL program analyzed routinely collected data from approximately 300,000 patients in six countries and found GLP-1 use was associated with lower rates of heart failure hospitalization and all-cause mortality compared with other glucose-lowering drugs, consistent with trial findings. And the ongoing SOUL trial (N=9,650) is testing oral semaglutide against placebo in type 2 diabetes with high cardiovascular risk, with results expected by late 2025, which will add the first oral GLP-1 CVOT data to the literature.

For prescribers starting a patient on a GLP-1 agent today, the practical monitoring schedule at HealthRX is: baseline TSH and calcitonin (in patients with any thyroid history), lipase (in patients with prior pancreatic disease), and renal function; repeat TSH at 6-8 weeks if on levothyroxine; monitor weight, blood pressure, and HbA1c at 3 months; and assess GI tolerance at each contact during the first 16-20 weeks of titration.